Weight Loss on Ozempic: Real Data & Individual Factors

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) clinical trials show participants lose an average of 5–15% of body weight over 68 weeks, though outcomes range from minimal loss to 20% reductions. Real-world data suggests variability is even greater, with response depending on dose, adherence, lifestyle, and individual metabolic factors.

Published weight loss numbers can mislead because they obscure the biological reasons some individuals respond dramatically while others see modest changes. PlexusDx believes precision wellness means understanding your own metabolic predispositions before treatment, not comparing yourself to population statistics.

Clinical Trial Data: What the Research Actually Shows

The SUSTAIN-6 trial, the pivotal Ozempic efficacy study, tracked 3,297 adults with type 2 diabetes over 68 weeks. At the 1.0 mg weekly dose, participants achieved mean weight loss of 4.0 kg (4.5% body weight). At 1.5–2.0 mg, losses reached 5.1 kg (5.8% body weight).

The STEP trials, which studied semaglutide for weight management in non-diabetic adults, demonstrated greater losses: 10.0–12.4 kg (10.1–12.5% body weight) at 1.0–2.4 mg weekly over 68 weeks. Higher doses and longer durations were associated with larger cumulative reductions.

Why Individual Weight Loss Outcomes Vary So Widely

GLP-1 medications work by slowing gastric emptying, reducing appetite signaling, and modulating blood glucose. But genetic variation in GLP1R (the receptor drug target), GIPR, FTO, and MC4R genes influences how efficiently each person's body responds to these signals.

Beyond genetics, real-world factors amplify variation: baseline BMI, degree of lifestyle adherence, existing metabolic disorders, concurrent medications, and gut microbiome composition all influence final weight loss. A person with optimal lifestyle compliance and favorable genetic markers may lose 18–22%, while someone with poor adherence and metabolically resistant variants may lose 3–5%.

Factor	Impact on Weight Loss Response
GLP1R receptor variants	Influence how efficiently the drug signal reaches appetite centers; some variants show 20–30% lower responsiveness
FTO gene polymorphisms	Associated with baseline obesity risk and metabolic rate; may predict initial weight and treatment plateau
Baseline BMI and weight	Higher baseline weights often show larger absolute losses but smaller percentage losses; metabolically complex obesity may show slower response
Lifestyle adherence (diet/exercise)	Consistent caloric deficit and physical activity can amplify weight loss by 5–8% beyond medication alone
Age and insulin sensitivity	Younger adults and those with better baseline insulin sensitivity often show faster early response
Gastrointestinal tolerance	Nausea, constipation, or intolerance may reduce adherence and limit cumulative weight loss

Real-World Data Beyond Clinical Trials

Observational studies and insurance claims data show wider variation than trials because real-world populations include incomplete adherence, dose reductions due to side effects, and intermittent use. Some analyses report median weight loss of 7–10% at 6 months, with a range of 0–25%.

Digital health platforms tracking semaglutide use report that approximately 30% of users achieve 15%+ weight loss, 50% achieve 5–15% loss, and 20% achieve less than 5%. Discontinuation due to side effects accounts for 10–15% of early non-responders, independent of genetic factors.

Who Should Expect Meaningful Weight Loss: Provider-Led Assessment

Effective candidates typically have baseline BMI ≥27 with comorbidity or BMI ≥30, stable metabolic disease, no absolute contraindications (history of medullary thyroid cancer, family history of MEN2), and readiness for lifestyle change. Realistic expectations—5–15% loss over 12–24 months—prevent disappointment and improve adherence.

Your healthcare provider should assess thyroid function, kidney function, blood pressure, current medications, and gastrointestinal history before initiation. Those with history of pancreatitis, severe gastroparesis, or active eating disorders require careful evaluation. Regular monitoring of weight, blood pressure, and glucose prevents adverse outcomes and guides dose adjustments.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes to provide context for your potential GLP-1 response profile. Carrying less responsive GLP1R variants may help explain why standard dosing yields modest results—context that informs discussions with your provider about dose escalation, adjunctive therapies, or alternative approaches.

The genetic test predicts predispositions in peptide metabolic pathways, not exact medication response. A person with favorable GLP1R and MC4R variants still requires lifestyle adherence and appropriate dosing to achieve weight loss. Conversely, someone with less favorable variants may still benefit significantly from treatment, especially with provider-guided optimization.

Understanding your genetic predispositions can support a more informed conversation with your provider about realistic timelines, appropriate starting doses, and whether additional biomarker testing (insulin levels, lipid panels, inflammatory markers) might inform your personalized treatment plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.